Although, numerous molecular predictors of prognosis have been developed to guide clinical decisions in the management of patients with BC, the scope for application of predictors has been somewhat limited; for example, Oncotype Dx was developed for prediction of prognosis only in cases with ER-positive, HER2-negative, node-negative, and early stage BC (Paik et al., 2004). This evidence concerns the gene ERBB2 and breast cancer.